Skip to main content
bioMérieux logo

bioMérieux — Investor Relations & Filings

Ticker · BIM ISIN · FR0013280286 LEI · 549300AK8Y0LBIQ4T071 PA Manufacturing
Open in API
Filings indexed 414 across all filing types
Latest filing 2024-01-16 Board/Management Inform…
Country FR France
Listing PA BIM

About bioMérieux

https://www.biomerieux.com/

bioMérieux is a global leader in the field of in vitro diagnostics, providing solutions that determine the source of disease and contamination. The company develops and manufactures diagnostic systems, reagents, and software for both clinical and industrial applications. In the clinical sector, its products are used for diagnosing infectious diseases, managing sepsis, combating antimicrobial resistance, and supporting cancer screening and cardiovascular emergencies. For industrial markets, bioMérieux offers microbiological control solutions to ensure the safety and quality of agri-food, pharmaceutical, and cosmetic products. These technologies provide rapid and reliable data to help healthcare professionals and industrial quality control managers make critical decisions that improve patient outcomes and ensure consumer safety.

Recent filings

Filing Released Lang Actions
bioMérieux announces nomination of two new Executive Committee members to lead Medical Affairs and R&D
Board/Management Information Classification · 100% confidence The document is a press release dated January 16th, 2024, announcing the nomination of two new Executive Committee members (Dr. Charles K. Cooper and Céline Roger-Dalbert) and detailing their roles and backgrounds. This content directly relates to changes in the company's senior management team. According to the definitions, 'Board/Management Information (Code: MANG)' covers the 'Announcement of changes in the company's board of directors or senior management.' The document is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI). Therefore, MANG is the most appropriate classification.
2024-01-16 English
bioMérieux nomme deux nouveaux membres dans son Comité de Direction pour diriger les Affaires Médicales et la R&D
Board/Management Information Classification · 100% confidence The document is a press release dated January 16, 2024, announcing the appointment of two new members to bioMérieux's Executive Committee (Comité de Direction): Dr. Charles K. Cooper (Chief Medical Officer) and Céline Roger-Dalbert (Executive VP R&D). This content directly relates to changes in senior management and the board structure. According to the definitions, 'Board/Management Information' (Code: MANG) covers the 'Announcement of changes in the company's board of directors or senior management.' The document is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI). Therefore, MANG is the most appropriate classification.
2024-01-16 French
bioMérieux acquires LUMED to reinforce its software portfolio in the fight against antimicrobial resistance
M&A Activity Classification · 99% confidence The document is a press release dated January 8th, 2024, announcing that bioMérieux has acquired the remaining stake in LUMED, increasing its ownership from 16% to 100%. This announcement details a corporate transaction (acquisition/financing activity) and includes quotes from management regarding the strategic rationale. This type of announcement, detailing a significant corporate transaction like an acquisition, best fits the 'Capital/Financing Update' category (CAP), as it involves a change in capital structure/ownership related to the transaction, or potentially 'Regulatory Filings' (RNS) if it were a mandatory filing, but given the content is a strategic announcement, CAP is more specific than RNS. It is not an earnings release (ER), a formal report (10-K, IR), or a management change (MANG). Since it is a specific announcement about a capital transaction (acquiring 84% of capital for ~9 million euros), CAP is the most appropriate classification.
2024-01-08 English
bioMérieux rachète LUMED pour consolider son portefeuille de logiciels dans la lutte contre l'antibiorésistance
M&A Activity Classification · 99% confidence The document is a press release dated January 8, 2024, announcing that bioMérieux has acquired the remaining stake in LUMED, a Canadian software company, to consolidate its portfolio in combating antimicrobial resistance. This type of announcement, detailing a significant corporate transaction (acquisition/takeover), aligns best with the Merger & Acquisition Activity (TAR) category. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a proxy statement. Since it is a specific announcement about a transaction, TAR is more precise than the general Regulatory Filings (RNS) fallback.
2024-01-08 French
Décembre 2023 - Déclaration sur le nombre d'actions composant le capital social et sur le nombre de droits de vote correspondant
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Informations mensuelles relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du code de commerce et l'article 223-16 du règlement général de l'Autorité des marchés financiers". This explicitly states it is a monthly report concerning the total number of voting rights and shares, as required by French commercial code and AMF regulations. This type of mandatory disclosure regarding share capital and voting rights, especially when presented in a structured table format for a specific date (31/12/2023), aligns best with regulatory reporting requirements that are not covered by the more specific categories like 10-K, ER, or DIV. Since it is a specific regulatory disclosure about share structure and voting rights, and not a general announcement of a report publication (RPA) or a general miscellaneous filing (RNS), it fits best under the general regulatory/disclosure category. Given the options, and noting that there isn't a specific 'Voting Rights Disclosure' code, this falls under the general 'Regulatory Filings' (RNS) as a mandatory periodic disclosure, although it is highly specific. However, upon reviewing the definitions, none perfectly match a mandatory monthly voting rights disclosure. It is a specific regulatory filing. If we must choose from the provided list, RNS is the most appropriate fallback for mandatory regulatory disclosures not explicitly listed. If we consider the content relates to share structure, SHA (Share Issue/Capital Change) is related but this is a periodic disclosure of existing structure, not an announcement of a change itself. Given the context of French mandatory disclosures, RNS is the safest general regulatory filing category.
2024-01-05 French
Novembre 2023 - Déclaration sur le nombre d'actions composant le capital social et sur le nombre de droits de vote correspondant
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Informations mensuelles relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du code de commerce et l'article 223-16 du règlement général de l'Autorité des marchés financiers". This explicitly indicates a monthly disclosure regarding the total number of voting rights and shares, as mandated by French commercial code and AMF regulations. This type of filing, which reports on share structure and voting rights, is most closely aligned with regulatory reporting concerning share capital changes or major shareholdings, but the specific nature points towards a mandatory disclosure related to share structure. Reviewing the definitions: - 10-K/IR: Not a full annual or interim financial report. - ER/MDA: Not an earnings release or management discussion. - DIRS: Not director's personal trades. - MRQ (Major Shareholding Notification): This is related to share structure, but MRQ usually refers to crossing ownership thresholds, whereas this is a mandatory monthly count. - SHA (Share Issue/Capital Change): This is a strong candidate as it relates to the total number of shares. - RNS (Regulatory Filings): This is a general regulatory filing. In the context of the provided codes, a mandatory monthly disclosure of total shares and voting rights (often required under Article 223-16 of the AMF General Regulation) is a specific type of regulatory filing concerning the capital structure. While SHA covers capital changes, this is a routine disclosure of the current state of shares/votes. Given the highly specific nature of the French regulatory requirement cited (L. 233-8 II and 223-16), and the lack of a perfect match for 'Monthly Voting Rights Disclosure', it falls under the general category of regulatory reporting concerning share capital. However, since it details the total number of shares and voting rights, it is fundamentally a report on the capital structure. If 'SHA' is interpreted broadly to cover official reports on the number of shares outstanding, it fits best. If not, 'RNS' is the fallback. Given the focus on the total number of shares ('Nombre d'actions'), SHA is the most relevant specific category related to capital structure reporting, even if it's not a 'new issue'. Revisiting the definitions, none perfectly capture the 'Monthly Voting Rights Disclosure'. However, since it reports the total number of shares (118,361,220), it is a report on the share count, making SHA (Share Issue/Capital Change) the closest fit among the specific options, as it deals directly with the share base. If this were a US filing, it might be an 8-K item 3.02, but here, SHA is the best fit for a report detailing the current share count.
2023-12-07 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.